GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine
- Conditions
- Acellular PertussisHaemophilus Influenzae Type bHepatitis BPoliomyelitisDiphtheriaTetanus
- Interventions
- Biological: Infanrix Hexa
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 403
- Registration Number
- NCT00627458
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
AED/Statin Interaction Study
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 119
- Registration Number
- NCT00627575
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00625196
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT00625859
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
- Conditions
- Infections, StreptococcalStreptococcus Pneumoniae Vaccines
- Interventions
- Biological: GSK1024805ABiological: PrevenarBiological: Infanrix hexaBiological: HavrixBiological: Varilrix
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 524
- Registration Number
- NCT00624819
- Locations
- 🇵🇱
GSK Investigational Site, Siemianowice Slaskie, Poland
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 348
- Registration Number
- NCT00624065
- Locations
- 🇺🇸
GSK Investigational Site, Beloit, Wisconsin, United States
Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-
- Conditions
- Atherosclerosis
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00622830
- Locations
- 🇯🇵
GSK Investigational Site, Ibaraki, Japan
Anti-MAG First Administration to Human
- Conditions
- Cerebrovascular Accident
- Interventions
- Drug: GSK249320ADrug: Placebo
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT00622609
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT00622388
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00621894
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of California San Diego Medical Center, San Diego, California, United States
🇺🇸Davis, Posteraro and Wasser, MD's LLP, Manchester, Connecticut, United States